By Ludwig Burger and Patricia Weiss
FRANKFURT (Reuters) – Unlisted biotech firm CureVac will become the second coronavirus vaccine developer to launch human trials of an experimental immunization in Germany, two people familiar with the plans told Reuters on Tuesday.
The clinical trial, which is scheduled to be announced on Wednesday, is the second clinical program to be approved by German vaccines regulator, the Paul Ehrlich Institute, following a study launched by domestic peer BioNTech in April.
CureVac and the Paul Ehrlich Institute declined to comment.
The World Health Organization lists 11 experimental vaccines against the virus that causes COVID-19 as currently being tested on humans, according to a table posted on its website.
(Reporting by Ludwig Burger and Patricia Weiss; Editing by Christoph Steitz)
